Pembrolizumab with enfortumab vedotin for untreated metastatic urothelial cancer ID6332
In development [GID-TA11233] Expected publication date: TBC
Search results
305 results
-
-
Eplontersen for treating polyneuropathy caused by hereditary transthyretin amyloidosis [ID6337]
In development [GID-TA11392] Expected publication date: 14 August 2024
-
Vibegron for treating symptoms of overactive bladder ID6300
In development [GID-TA11348] Expected publication date: TBC
-
Tucatinib with trastuzumab for previously treated HER2-positive colorectal cancer [ID6227]
In development [GID-TA11228] Expected publication date: 25 September 2024
-
Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]
In development [GID-TA11423] Expected publication date: 11 December 2024
-
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]
In development [GID-TA11425] Expected publication date: TBC
-
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]
In development [GID-TA11408] Expected publication date: TBC
-
DCVax-L for treating glioblastoma [ID836]
In development [GID-TA10143] Expected publication date: TBC
-
Alectinib for adjuvant treatment of ALK-positive non-small-cell lung cancer [ID6368]
In development [GID-TA11436] Expected publication date: 11 December 2024
-
Sparsentan for treating primary IgA nephropathy ID6308
In development [GID-TA11359] Expected publication date: 11 December 2024
-
Vepdegestrant for treating hormone receptor-positive HER2-negative metastatic breast cancer after endocrine treatment [ID6360]
In development [GID-TA11400] Expected publication date: TBC
-
Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]
In development [GID-TA11401] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]
In development [GID-TA10826] Expected publication date: TBC
-
Efgartigimod for treating generalised myasthenia gravis [ID4003]
In development [GID-TA10986] Expected publication date: 24 July 2024
-
Exagamglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID4015]
In development [GID-TA11250] Expected publication date: TBC
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: TBC
-
Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma [Review of TA658] [ID4067]
In development [GID-TA10979] Expected publication date: TBC
-
Elranatamab for treating relapsed or refractory multiple myeloma after 3 therapies [ID4026]
In development [GID-TA10918] Expected publication date: 05 June 2024
-
Rozanolixizumab for treating antibody-positive generalised myasthenia gravis [ID5092]
In development [GID-TA10994] Expected publication date: TBC
-
Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (MA review of TA781) [ID6287]
In development [GID-TA11484] Expected publication date: 26 February 2025
-
Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]
In development [GID-TA10615] Expected publication date: TBC
-
Belzutifan for previously treated advanced renal cell carcinoma [ID6154]
In development [GID-TA11086] Expected publication date: TBC
-
Trifluridine–tipiracil with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments [ID6298]
In development [GID-TA11390] Expected publication date: 24 July 2024
-
Sotatercept for treating pulmonary arterial hypertension [ID6163]
In development [GID-TA11103] Expected publication date: TBC
-
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]
In development [GID-TA10980] Expected publication date: 17 July 2024
-
Pembrolizumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID5094]
In development [GID-TA11174] Expected publication date: 16 October 2024
-
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907]
In development [GID-TA10784] Expected publication date: 16 October 2024
-
Cerliponase alfa for treating neuronal ceroid lipofuscinosis type 2 (review of HST12) [ID6145]
In development [GID-TA11391] Expected publication date: 23 October 2024
-
Faricimab for treating macular oedema caused by retinal vein occlusion [ID6197]
In development [GID-TA11148] Expected publication date: 14 August 2024
-
Pembrolizumab with chemoradiation for untreated high-risk locally advanced cervical cancer [ID6138]
In development [GID-TA11215] Expected publication date: TBC
-
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment ID6370
In development [GID-TA11513] Expected publication date: TBC
-
ONS-5010 for treating wet age-related macular degeneration ID6320
In development [GID-TA11193] Expected publication date: TBC
-
Tafamidis for treating transthyretin amyloidosis with cardiomyopathy [ID6327]
In development [GID-TA11389] Expected publication date: 12 June 2024
-
Pembrolizumab with chemotherapy for adjuvant treatment of newly diagnosed high-risk endometrial cancer after surgery with curative intent ID6207
In development [GID-TA11235] Expected publication date: TBC
-
Pegcetacoplan for treating geographic atrophy [ID4041]
In development [GID-TA11351] Expected publication date: TBC
-
SQ HDM SLIT for treating allergic rhinitis and allergic asthma caused by house dust mites (review of TA834) [ID6280]
In development [GID-TA11355] Expected publication date: 09 July 2024
-
Teclistamab for treating relapsed or refractory multiple myeloma after 3 treatments (Review of TA869) [ID6333]
In development [GID-TA11418] Expected publication date: 14 August 2024
-
Empagliflozin for preventing cardiovascular events after acute myocardial infarction ID6240
In development [GID-TA11265] Expected publication date: TBC
-
Voxelotor for treating sickle cell disease [ID1403]
In development [GID-TA10505] Expected publication date: 05 June 2024
-
Efanesoctocog alfa for treating and preventing bleeding episodes in haemophilia A [ID6170]
In development [GID-TA11106] Expected publication date: TBC
-
Pirtobrutinib for treating chronic lymphocytic leukaemia or small lymphocytic lymphoma after 1 or more BTK inhibitors [ID6269]
In development [GID-TA11298] Expected publication date: TBC
-
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
In development [GID-TA10733] Expected publication date: TBC
-
Sipavibart for preventing COVID-19 [ID6282]
In development [GID-TA11352] Expected publication date: 26 February 2025
-
Iptacopan for treating paroxysmal nocturnal haemoglobinuria [ID6176]
In development [GID-TA11132] Expected publication date: 26 June 2024
-
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]
In development [GID-TA11220] Expected publication date: 17 July 2024
-
Avapritinib for treating advanced systemic mastocytosis ID3770
In development [GID-TA11382] Expected publication date: TBC
-
Abaloparatide for treating osteoporosis in postmenopausal women [ID882]
In development [GID-TA10071] Expected publication date: TBC
-
Durvalumab with platinum-based chemotherapy, then with or without olaparib, for untreated advanced or recurrent endometrial cancer ID6317
In development [GID-TA11340] Expected publication date: TBC
-
Ublituximab for treating relapsing–remitting multiple sclerosis ID6350
In development [GID-TA11268] Expected publication date: TBC
-
Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable ID6218
In development [GID-TA11139] Expected publication date: TBC